<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944759</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSURECS/30042019/Ali</org_study_id>
    <nct_id>NCT03944759</nct_id>
  </id_info>
  <brief_title>Efficacy of Serratus Anterior Plane Block Mastectomy</brief_title>
  <official_title>Efficacy of Serratus Anterior Plane Block Using Bupivacaine/Magnesium Sulphate Versus Bupivacaine/Nalbuphine for Mastectomy: a Randomized Double Blinded Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>doaa rashwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the main common cancer among females. . Inadequate control of pain may later
      develop into chronic pain syndrome (paraesthesias, phantom breast pain, and
      intercostobrachial neuralgia) in 25-40% of the patients .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the efficacy of ultrasound-guided serratus anterior plane
      block with bupivacaine/ magnesium versus bupivacaine/ nalbuphine in breast cancer surgery.

      Patients and methods nclusion criteria:

      -ASA I and II female patients, age 25-60 undergoing breast cancer surgery

      Exclusion criteria:

        -  Patient refusal

        -  Contraindications for regional blocks (eg. Infection at the injection site,
           coagulopathy)

        -  Allergy to the drugs used in the study

        -  Chronic pain therapy,

        -  BMI more than 30 kg/m2
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first analgesic requirements in minutes</measure>
    <time_frame>change from base line for 24 hours</time_frame>
    <description>time to first analgesic requirements in minutes by the patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>GBM:( bupivacaine/magnesium sulphate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.
GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBN: ( bupivacaine/nalpuphin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>serratus anterior plan block</intervention_name>
    <description>serratus anterior plan block</description>
    <arm_group_label>GBM:( bupivacaine/magnesium sulphate)</arm_group_label>
    <arm_group_label>GBN: ( bupivacaine/nalpuphin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I and II female patients, age 25-60 undergoing breast cancer surgery

        Exclusion Criteria:

          -  -Patient refusal

          -  Contraindications for regional blocks (eg. Infection at the injection site,
             coagulopathy)

          -  Allergy to the drugs used in the study

          -  Chronic pain therapy,

          -  BMI more than 30 kg/m2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doaa Rashwan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine Beni-Suef University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Of Medicine, Beni-Suef University</name>
      <address>
        <city>BanÄ« Suwayf</city>
        <zip>11391</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>doaa rashwan</investigator_full_name>
    <investigator_title>Assistant profesor Doaa Rashwan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>the protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>after registration for ever</ipd_time_frame>
    <ipd_access_criteria>on the web page
-</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

